Peroxiredoxin 4: A novel secreted mediator of cancer induced osteoclastogenesis

Cancer Letters

Volumn 361, Issue 2, 2015, Pages 262-270

  Rafiei, Shahrzad ^a,b   Tiedemann, Kerstin ^a,b   Tabariès, Sébastien ^c   Siegel, Peter M ^c,d,e   Komarova, Svetlana V ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Bone; Breast cancer; Metastasis; Osteoclast; PRDX4; Prostate cancer

Indexed keywords

MESSENGER RNA; PEROXIREDOXIN 4; PEROXIREDOXIN; PRDX4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CARCINOGENESIS; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; ANIMAL; BONE DEVELOPMENT; BONE TUMOR; BREAST TUMOR; DEFICIENCY; FEMALE; GENE SILENCING; GENETICS; MCF 7 CELL LINE; METABOLISM; METASTASIS; NUDE MOUSE; OSTEOCLAST; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASM METASTASIS; OSTEOCLASTS; OSTEOGENESIS; PEROXIREDOXINS; PROSTATIC NEOPLASMS;

EID: 84926119342     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.012     Document Type: Article

References (45)

1. Hess K.R., Varadhachary G.R., Taylor S.H., Wei W., Raber M.N., Lenzi R., et al. Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624-1633.
2. Kerba M., Miao Q., Zhang-Salomons J., Mackillop W. Defining the need for prostate cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin. Oncol. (R. Coll. Radiol.) 2010, 22:801-809.
3. Keller E.T., Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell. Biochem 2004, 91:718-729.
4. Taube T., Elomaa I., Blomqvist C., Beneton M.N., Kanis J.A. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994, 15:161-166.
5. Wada T., Nakashima T., Hiroshi N., Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med 2006, 12:17-25.
6. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593.
7. Ibrahim T., Flamini E., Mercatali L., Sacanna E., Serra P., Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010, 116:1406-1418.
8. Guo Y., Tiedemann K., Khalil J.A., Russo C., Siegel P.M., Komarova S.V. Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone 2008, 43:386-393.
9. 2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways. J. Biol. Chem 2009, 284:33662-33670.
10. Hussein O., Tiedemann K., Murshed M., Komarova S.V. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 2012, 314:176-184.
11. Rafiei S., Komarova S.V. Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells. BMC Cancer 2013, 13:605.
12. Wood Z.A., Poole L.B., Karplus P.A. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 2003, 300:650-653.
13. Butterfield L.H., Merino A., Golub S.H., Shau H. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid. Redox Signal 1999, 1:385-402.
14. Wood Z.A., Schroder E., Robin Harris J., Poole L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci 2003, 28:32-40.
15. Wong C.M., Chun A.C., Kok K.H., Zhou Y., Fung P.C., Kung H.F., et al. Characterization of human and mouse peroxiredoxin IV: evidence for inhibition by Prx-IV of epidermal growth factor- and p53-induced reactive oxygen species. Antioxid. Redox Signal 2000, 2:507-518.
16. Matsumoto A., Okado A., Fujii T., Fujii J., Egashira M., Niikawa N., et al. Cloning of the peroxiredoxin gene family in rats and characterization of the fourth member. FEBS Lett 1999, 443:246-250.
17. Okado-Matsumoto A., Matsumoto A., Fujii J., Taniguchi N. Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J. Biochem 2000, 127:493-501.
18. Jin D.Y., Chae H.Z., Rhee S.G., Jeang K.T. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J. Biol. Chem 1997, 272:30952-30961.
19. Haridas V., Ni J., Meager A., Su J., Yu G.L., Zhai Y., et al. TRANK, a novel cytokine that activates NF-kappa B and c-Jun N-terminal kinase. J. Immunol 1998, 161:1-6.
20. Tavender T.J., Sheppard A.M., Bulleid N.J. Peroxiredoxin IV is an endoplasmic reticulum-localized enzyme forming oligomeric complexes in human cells. Biochem. J. 2008, 411:191-199.
21. Karihtala P., Mantyniemi A., Kang S.W., Kinnula V.L., Soini Y. Peroxiredoxins in breast carcinoma. Clin. Cancer Res 2003, 9:3418-3424.
22. Basu A., Banerjee H., Rojas H., Martinez S.R., Roy S., Jia Z., et al. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 2011, 71:755-765.
23. Shen C., Nathan C. Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol. Med 2002, 8:95-102.
24. Rhodes D.R., Chinnaiyan A.M. Integrative analysis of the cancer transcriptome. Nat. Genet 2005, 37(Suppl.):S31-S37.
25. Tabaries S., Dong Z., Annis M.G., Omeroglu A., Pepin F., Ouellet V., et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011, 30:1318-1328.
26. Ryser M.D., Qu Y., Komarova S.V. Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput. Biol 2012, 8:e1002703.
27. Kim N., Takami M., Rho J., Josien R., Choi Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med 2002, 195:201-209.
28. Cella M., Buonsanti C., Strader C., Kondo T., Salmaggi A., Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J. Exp. Med 2003, 198:645-651.
29. Dowling P., Clynes M. Conditioned media from cell lines: a complementary model to clinical specimens for the discovery of disease-specific biomarkers. Proteomics 2011, 11:794-804.
30. Boyce B.F., Yoneda T., Guise T.A. Factors regulating the growth of metastatic cancer in bone. Endocr. Relat. Cancer 1999, 6:333-347.
31. Wong G.S., Rustgi A.K. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br. J. Cancer 2013, 108:755-761.
32. Onnis B., Fer N., Rapisarda A., Perez V.S., Melillo G. Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. J. Clin. Invest 2013, 123:1615-1629.
33. Darnay B.G., Haridas V., Ni J., Moore P.A., Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J. Biol. Chem 1998, 273:20551-20555.
34. Robinson M.W., Hutchinson A.T., Dalton J.P., Donnelly S. Peroxiredoxin: a central player in immune modulation. Parasite Immunol 2010, 32:305-313.
35. Pilch B., Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol 2006, 7:R40.
36. Flaherty C.O., de Souza A.R. Hydrogen peroxide modifies human sperm peroxiredoxins in a dose-dependent manner. Biol. Reprod 2011, 84:238-247.
37. Iuchi Y., Okada F., Tsunoda S., Kibe N., Shirasawa N., Ikawa M., et al. Peroxiredoxin 4 knockout results in elevated spermatogenic cell death via oxidative stress. Biochem. J. 2009, 419:149-158.
38. Kumar B., Koul S., Khandrika L., Meacham R.B., Koul H.K. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008, 68:1777-1785.
39. Karihtala P., Kauppila S., Soini Y., Arja Jukkola V. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 2011, 11:262.
40. Radyuk S.N., Klichko V.I., Michalak K., Orr W.C. The effect of peroxiredoxin 4 on fly physiology is a complex interplay of antioxidant and signaling functions. FASEB J. 2013, 27:1426-1438.
41. Huh Y.J., Kim J.M., Kim H., Song H., So H., Lee S.Y., et al. Regulation of osteoclast differentiation by the redox-dependent modulation of nuclear import of transcription factors. Cell Death Differ 2006, 13:1138-1146.
42. Ha H., Kwak H.B., Lee S.W., Jin H.M., Kim H.M., Kim H.H., et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp. Cell Res 2004, 301:119-127.
43. Kim H., Kim I.Y., Lee S.Y., Jeong D. Bimodal actions of reactive oxygen species in the differentiation and bone-resorbing functions of osteoclasts. FEBS Lett 2006, 580:5661-5665.
44. Le Nihouannen D., Barralet J.E., Fong J.E., Komarova S.V. Ascorbic acid accelerates osteoclast formation and death. Bone 2010, 46:1336-1343.
45. Varambally S., Yu J., Laxman B., Rhodes D.R., Mehra R., Tomlins S.A., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8:393-406.